Delivery strategies to target therapies to inflammatory tissue

Expert Opinion on Drug Delivery

Volumn 5, Issue 7, 2008, Pages 767-774

  VanAuker, Michael D ^a   Hood, Elizabeth ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Adhesion molecules; Chemokines; Cytokines; Inflammation; Liposomes; Monoclonal antibodies; Nanoparticles

Indexed keywords

ANTIINFLAMMATORY AGENT; DEXAMETHASONE; DRUG CARRIER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOCORTICOID; HERMES ANTIGEN; IMMUNOLIPOSOME; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; LIPOSOME; MACROGOL; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGODEXTRAN POLYMER; PADGEM PROTEIN; POLYGLACTIN; POLYMER; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ADRENAL INSUFFICIENCY; ANGIOGENESIS; ARTHRITIS; ATHEROSCLEROSIS; BONE DISEASE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CROHN DISEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INFLAMMATORY DISEASE; LUNG DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SKIN DISEASE; VASCULAR DISEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS; CHRONIC DISEASE; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; LUNG DISEASES; VASCULAR DISEASES;

EID: 48449104666     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.7.767     Document Type: Review

References (61)

1. Meager A. Cytokine regulation of cellular adhesion molecule expression in inflammation. Cytokine Growth Factor Rev 1999;10(1):27-39
2. Golias C, Tsoutsi E, Matziridis A, et al. Review. Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease. In vivo 2007;21(5):757-69
3. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003;170(2):191-203
4. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999;52(4):189-96
5. Woodside DG, Vanderslice P. Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease. BioDrugs 2008;22(2):85-100
6. O'Brien KD, Allen MD, McDonald TO, et al. Vascular cell-adhesion molecule-1 is expressed in human coronary atherosclerotic plaques - implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 1993;92(2):945-51
7. Voinea M, Simionescu M. Designing of 'intelligent' liposomes for efficient delivery of drugs. J Cell Mol Med 2002;6(4):465-74
8. Qin J, Chen D, Hu H, et al. Body distribution of RGD-mediated liposome in brain-targeting drug delivery. Yakugaku Zasshi 2007;127(9):1497-501
9. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev 2003;83(4):1069-112
10. Bombardieri M, McInnes IB, Pitzalis C. Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions. Exp Opin Biol Ther 2007;7(1):31-40
11. Dinesen L, Travis S. Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870). Int J Nanomed 2007;2(1):39-47
12. Chono S, Morimoto K. Uptake of dexamethasone incorporated into liposomes by macrophages and foam cells and its inhibitory effect on cellular cholesterol ester accumulation. J Pharm Pharmacol 2006;58(9):1219-25
13. Antohe F, Lin L, Kao GY, et al. Transendothelial movement of liposomes in vitro mediated by cancer cells, neutrophils or histamine. J Liposome Res 2004;14(1-2):1-25
14. Trachsel E, Kaspar M, Bootz F, et al. A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo. J Invest Dermatol 2007;127(4):881-6
15. Cazzola M, Ciaprini C, Page CP, Matera MG. Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease. Exp Opin Ther Targets 2007;11(10):1273-86
16. Choi JS, Shin SC. Preparation and evaluation of pranoprofen gel for percutaneous administration. Drug Dev Ind Pharm 2007;33(1):19-26
17. Patil SD, Papadmitrakopoulos F, Burgess DJ. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J Control Release 2007;117(1):68-79
18. Yeo Y, Adil M, Bellas E, et al. Prevention of peritoneal adhesions with an in situ cross-linkable hyaluronan hydrogel delivering budesonide. J Control Release 2007;120(3):178-85
19. Libby P. Inflammation in atherosclerosis. Nature 2002;420(6917):868-74
20. Koopman G, Taher TEI, Mazzucchelli I, et al. CD44 isoforms, including the CD44 V3 variant, are expressed on endothelium, suggesting a role for CD44 in the immobilization of growth factors and the regulation of the local immune response. Biochem Biophys Res Commun 1998;245(1):172-6
21. Krettek A, Sukhova GK, Schonbeck U, Libby P. Enhanced expression of CD44 variants in human atheroma and abdominal aortic aneurysm - possible role for a feedback loop in endothelial cells. Am J Pathol 2004;165(5):1571-81
22. DeGrendele HC, Estess P, Picker LJ, Siegelman MH. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway. J Exp Med 1996;183(3):1119-30
23. Pure E, Cuff CA. A crucial role for CD44 in inflammation. Trends Mol Med 2001;7(5):213-21
24. Mullenix PS, Andersen CA, Starnes BW. Atherosclerosis as inflammation. Ann Vasc Surg 2005;19(1):130-8
25. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007;14(1):55-61
26. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135-43
27. Cybulsky MI, Iiyama K, Li HM, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107(10):1255-62
28. Tsouknos A, Nash GB, Rainger GE. Monocytes initiate a cycle of leukocyte recruitment when cocultured with endothelial cells. Atherosclerosis 2003;170(1):49-58
29. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92(5):1355-74
30. Schneider F, Sukhova GK, Aikawa M, et al. Matrix-metalloproteinase-14 deficiency in bone-marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques. Circulation 2008;117(7):931-9
31. Welgus HG, Senior RM, Parks WC, et al. Neutral proteinase expression by human mononuclear phagocytes: a prominent role of cellular differentiation. Matrix 1992;1:363-7
32. Torchilin VP. Targeting of drugs and drug carriers within the cardiovascular-system. Adv Drug Deliv Rev 1995;17(1):75-101
33. Price RJ, Kaul S. Contrast ultrasound targeted drug and gene delivery: an update on a new therapeutic modality. J Cardiovasc Pharmacol Ther 2002;7(3):171-80
34. Lindner JR. Detection of inflamed plaques with contrast ultrasound. Am J Cardiol 2002;90(10C):L32-5
35. Dayton PA, Ferrara KW. Targeted imaging using ultrasound. J Magn Reson Imaging 2002;16(4):362-77
36. Torchilin VP. Targeting of liposomes within cardiovascular system. J Liposome Res 1997;7(4):433-54
37. Muzykantov VR. Targeting of superoxide dismutase and catalase to vascular endothelium. J Control Release 2001;71(1):1-21
38. Muro S, Muzykantov VR. Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. Curr Pharm Des 2005;11(18):2383-401
39. Asgeirsdóttir SA, Kamps JA, Bakker HI, et al. Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol Pharmacol 2007;72(1):121-31
40. Woollard KJ, Chin-Dusting J. Therapeutic targeting of p-selectin in atherosclerosis. Inflamm Allergy Drug Targets 2007;6(1):69-74
41. Gee K, Kryworuchko M, Kumar A. Recent advances in the regulation of CD44 expression and its role in inflammation and autoimmune diseases. Arch Immunol Ther Exp 2004;52(1):13-26
42. Cuff CA, Kothapalli D, Azonobi I, et al. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest 2001;108(7):1031-40
43. Hood E, Gonzalez M, Plaas A, et al. Immuno-targeting of nonionic surfactant vesicles to inflammation. Int J Pharm 2007;339(1-2):222
44. Lestini BJ, Sagnella SM, Xu Z, et al. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J Control Release 2002;78(1-3):235-47
45. Desai TR, Finlay WH. Nebulization of niosomal all-trans-retinoic acid: an inexpensive alternative to conventional liposomes. Int J Pharm 2002;241(2):311-7
46. Christofidou-Solomidou M, Scherpereel A, Wiewrodt R, et al. PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am J Physiol Lung Cell Mol Physiol 2003;285(2):L283-92
47. Otsubo T, Maruyama K, Maesaki S, et al. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice. Antimicrob Agents Chemother 1998;42(1):40-4
48. Murciano JC, Muro S, Koniaris L, et al. ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood 2003;101(10):3977-84
49. Mastrobattista E, Storm G, van Bloois L, et al. Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells. Biochim Biophys Acta 1999;1419(2):353-63
50. Barnes PJ. Emerging targets for COPD therapy. Curr Drug Targets Inflamm Allergy 2005;4(6):675-83
51. Gaggar A, Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008;180(8):5662-9
52. Foged C, Nielsen HM, Frokjaer S. Liposomes for phospholipase A2 triggered siRNA release: preparation and in vitro test. Int J Pharm 2007;331(2):160-6
53. Lu Y, Zhang G, Sun D, Zhong Y. Preparation and evaluation of biodegradable flubiprofen gelatin micro-spheres for intra-articular administration. J Microencapsul 2007;24(6):515-24
54. Chandrasekar D, Sistla R, Ahmad FJ, et al. Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery. J Biomed Mater Res A 2007;82(1):92-103
55. Tsai CY, Shiau AL, Chen SY, et al. Amelioration of collagen-induced arthritis in rats by nanogold. Arthritis Rheum 2007;56(2):544-54
56. Ludwig RJ, Schön MP, Boehncke WH. P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. Exp Opin Ther Targets 2007;11(8):1103-17
57. Van Eldik LJ, Thompson WL, Ralay Ranaivo H, et al. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int Rev Neurobiol 2007;82:277-96
58. Pellequer Y, Meissner Y, Ubrich N, Lamprecht A. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J Pharmacol Exp Ther 2007;321(2):726-33
59. Lajavardi L, Bochot A, Camelo S, et al. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes. Invest Ophthalmol Vis Sci 2007;48(7):3230-8
60. Adibkia K, Siahi Shadbad MR, Nokhodchi A, et al. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target 2007;15(6):407-16
61. Gojova A, Guo B, Kota RS, et al. Induction of inflammation in vascular endothelial cells by metal oxide nanoparticles: effect of particle composition. Environ Health Perspect 2007;115(3):403-9